AHN-GOOK PHARMACEUTICAL Co., Ltd.
KKRX:0015409,250.00
KRW
-90.00
(-0.96%)
ISIN
KR7001540004
Return %
Stock
S&P 500
1Y
18.74
14.39
3Y
25.85
81.42
5Y
-11.90
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 424
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Gwacheon-si South Korea
- IPO Date
- Jun 15, 2000
- Website
- ahn-gook.com
- Similar Companies
- Business
- AHN-GOOK PHARMACEUTICAL Co., Ltd. is a South Korea-based biopharmaceutical company engaged in the research, development, manufacture, and commercialization of prescription pharmaceuticals, over-the-counter medicines, health functional foods, and healthcare solutions. Founded in 1955 and headquartered in Gwacheon-si, Gyeonggi-do, South Korea, the company operates advanced manufacturing facilities in Hyangnam, Hwaseong-si, alongside dedicated research and development institutes. The company operates primarily within human therapeutics, focusing on respiratory, cardiovascular, gastrointestinal, ophthalmic, and metabolic disease management. The company's core product portfolio encompasses respiratory agents, including Synatura Syrup, a natural herbal expectorant and antitussive formulation for acute upper respiratory infections and chronic bronchitis, and Anycough capsules; cardiovascular therapies, including Levotension and Levosartan for the treatment of hypertension, as well as Pevarozet for dyslipidemia management; gastrointestinal products, including Letopra; antihistamines and allergy treatments, including Rupafin; ophthalmic treatments and health supplements, including the Tobicom product line; and active pharmaceutical ingredients and diagnostic products developed through its affiliate network, which includes AGBIO Diagnostics, Ahn-gook Newpharm, and Anguk Health. The company distributes its products to general hospitals, clinics, and retail pharmacies across South Korea while expanding export operations to international markets in Southeast Asia, Central America, and the Middle East. In recent operational and strategic developments under its long-term growth vision, Ahn-Gook Pharmaceutical entered into an exclusive domestic licensing and distribution agreement with George Medicines to commercialize WIDAPLIK (GMRx2), an innovative triple-combination therapy indicated for initial hypertension management. The company also signed a strategic research memorandum of understanding with Cellbion Co., Ltd. to jointly develop next-generation targeted radiopharmaceuticals and cancer therapy platforms. Expanding beyond traditional therapeutics, Ahn-Gook Pharmaceutical diversified into the advanced medical materials sector through a strategic partnership with SOFNT, completed the acquisition of Dimedi Korea to broaden its footprint in health technology and consumer healthcare segments, established a strategic bio-health investment fund in partnership with Mirae Asset Capital, and completed the relocation of its corporate headquarters and central research laboratories to the Gwacheon Knowledge and Information Town to consolidate administrative and research operations across its affiliated entities.